Volume : 09, Issue : 05, May – 2022
Title:
06.COMPARISON OF DRUG APPROVAL PROCESS IN UNITED STATES, INDIA & EUROPE
Authors :
Uppu Mohan Krishna*, Korabandi Rajani, Kunda Vandana, M.V. Nagabhushanam, Brahmaiah Bonthagarala, G. Ramakrishna, Y. Ratna Sindhu, Santosh Kumar Ch
Abstract :
Wellbeing and viability of a medication item for use in people is fundamental before the medication item can be endorsed for import or assembling a new medication. For this each nation has administrative power bears the obligation of assessing whether the exploration information of new drug/item upholds the security and viability to serve general wellbeing. Administrative issue branch of an organization assumes a crucial part of working in understanding to the principles, guidelines and rules laid out by the directing organizations of various nations. This article expects to look at changed parts of medication endorsement process in USA, Europe, India and Japan.
Keywords: DRUG APPROVAL PROCESS, FDA, EMA, PMDA, CDSCO, MAA, NDA, INDA, ANDA
Cite This Article:
Please cite this article in press Uppu Mohan Krishna et al, Comparison Of Drug Approval Process In United States, India & Europe., Indo Am. J. P. Sci, 2022; 09(5).,
Number of Downloads : 10
References:
1. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 201
2. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 202
3. Kashyap UN, Gupta V, Raghunandan HV. Comparison of drug approval Process in United States & Europe. Journal of pharmaceutical sciences and research, 2013; 5(6): 131-136.
4. Prajapati V, Goswami R, Makvana P, Badjatya JK. A review on drug approval process for US, Europe and India. International Journal of Drug Regulatory Affairs, 2014; 2(1): 1- 11.
5. Swapna G, Bindhu Madhavi. Ch2, Anusha P Rupa T, Mohini D1 , Venkkana B. Comparatively study of dossier submission process for drug product in USA, EU & Indian Regulatory. World Journal of Pharmaceutical Research, 2014; 3(6): 406-411.
6. Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in “BRICS” Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 20-39.
7. Brahmaiah Bonthagarala, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, Issue 6 volume 6, November-December 2016, 144-157.
8. Brahmaiah Bonthagarala, Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 1-19.
9. Brahmaiah Bonthagarala, Nanomedicine Clinical Use, Regulatory And Toxicology Issues In Europe, Journal of Drug Delivery and Therapeutics, 2019; 9(4-s):846-848.